Index

active gene–environment correlation (GEr) 57
adolescents
  see also depression and anxiety in children and adolescents
  major depression 297
  adoptee-as-proband study design 36
  adoption studies 36–7
  adverse effects of medication 159–60
  affected relative pair method 39–40
  age
    attention deficit hyperactivity disorder (ADHD) 452–3
    depression and anxiety in children and adolescents 438–9
    dysthymia 303
    eating disorders 352–3
    major depression 296–7
    panic disorder 314
    schizophrenia 268–9
Aging, Demographics and Memory Study (ADAMS) 541
agoraphobia
  definition 316
  rates 316
  relationship with other anxiety disorders 317
  risk factors 316–17
alcohol 361, 374–5
  abuse in Latin American populations in USA 600–1
  bipolar disorder (BPD) 333, 334
  chronic disease 366–7
  comorbidity with other psychiatric disorders 371–4
  consumption 361–2
  course of disorders 368–71
  diagnostic classification of use disorders 367–8
  fetal exposure and ADHD 457
  genes, culture and health 175–6
  injuries 365–6
  mortality and morbidity 365
  attributable deaths 369–70
  prevalence of drinking 362–5
  alcohol dependence syndrome (ADS) 367–8
  alcohol use disorders (AUDs) 368
  alpha coefficient 75, 76, 77
  analysis of variance (ANOVA) 15
    one-way 79–80
    two-way 80–1
  anorexia nervosa (AN) see eating disorders
  antisocial personality disorder (APD) 402, 410–11
  anxiety disorders 311–13
  see also depression and anxiety in children and adolescents
  aftermath of mass disasters 320–1
    Hurricane Katrina 321
    limitation of epidemiologic studies 322
    September 11 terrorist attacks 321
    tsunami in southern Thailand 321–2
  agoraphobia
    definition 316
    rates 316
    relationship with other anxiety disorders 317
    risk factors 316–17
  epidemiological community surveys 312
  future developments 323
  generalised anxiety disorder (GAD)
    definition 318
anxiety disorders (continued)
  
  rates 318–19
  risk factors 319

obsessive–compulsive disorder (OCD)
  
  definition 319–20
  rates 320
  risk factors 320

panic disorder
  
  comorbid psychiatric disorder 315–16
  definition 313
  rates 313–14
  risk factors 314–15

social phobia
  
  definition 317
  rates 317–18
  risk factors 318

ascertainment bias 246

Asperger’s syndrome 469, 470–1

association studies 41–4

attempted suicide see suicide and attempted suicide

attention deficit hyperactivity disorder (ADHD)
  
  333, 449–50, 460
  
  comorbid psychiatric disorders 451–2
  
  demographic risk factors
  
  age 452–3
  ethnicity 453
  gender 452
  socioeconomic status 453
  
  environmental risk factors
  
  diet 457
  
  fetal exposure to alcohol 457
  
  fetal exposure to maternal smoking 458
  
  pregnancy and delivery problems 457
  
  psychosocial adversity 458–9
  
  television watching 459–60
  
  toxin exposure 457

future directions 460–1

 genetic risk factors
  
  candidate gene studies 454–6
  
  dopamine D4 receptor 454
  
  dopamine D5 receptor 454–5
  
  dopamine transporter gene (DAT1, SLC6A3) 455–6
  
  family, twin and adoption studies 453
  
  gene linkage studies 454, 455
  
  genome-wide association studies 456–7
  
  molecular genetics 453–6
  
  serotonin 1B receptor 456
  
  serotonin transporter (HTT, SLC6A4) 456
  
  synaptosomal associated protein of 25 kD (SNAP25) 456
  
  pharmacoconomics 451
  
  prevalence 450–1

attrition
  
  definition 192–3

autism spectrum disorder (ASD) 469, 478

  associations and causal factors 477
  
  behavioural and educational interventions 474–5
  
  definition and diagnosis 469–72
  
  future directions 477–8
  
  genetic factors 476
  
  natural history 472–3
  
  prevalence 473
  
  prevalence 475
  
  public health impact 476–7
  
  risk factors 473–6

avoidant personality disorder 416

Beck Depression Inventory (BDI) 205–6, 103–4

Berkson’s Fallacy 89

bias 4–6

  controlling 245
  
  accounting for participants 247
  
  blinding (masking) of treatment allocation 246
  
  empirical evidence of bias 247–8
  
  maximising follow-up 247
  
  randomisation with allocation concealment 245–6

binge eating disorder (BED) see eating disorders

binomial probability distribution 10–11

bipolar disorder (BPD) 329, 338

  comorbidity patterns
  
  mental disorders 333–4
  
  non-psychiatric medical disorders 334

epidemiology
  
  adults 329–31
  
  youth 331–3

future directions 336–7

  comorbidity with mental and physical disorders 338
  
  diagnostic spectrum 337
  
  research integration for adults and children 337–8

risk factors 334–5

  family history/genetics 335–6

  proband studies 336
INDEX

birth complications
  schizophrenia 276–7
blinding of treatment allocation 246
blood alcohol content (BAC) 366
borderline personality disorder (BPD) 411
bulimia nervosa (BN) see eating disorders
buspirone 155
Calgary Depression Scale (CDS) 103–4
Camberwell Assessment of Need (CAN) inventory 149
carbamazepine 155
career of psychopathology 190
case only studies 63–4
case parent trio studies 64
case–control association study 42
case–control studies 5, 11, 56, 63
  genetic and environmental bases of psychiatric disorders 89
causal gene–environment correlation (GER) 57
causal inference 6–7
causation 2–3
  alternative explanations 3–4
    bias 4–6
    confounding 4
    reverse causation 6
    sampling variation and chance 4
examples 174
  alcohol 175–6
  birthweight 176–7
  neighbourhood and ethnic density 174–5
  parental age 174
  schizophrenia 176
  violence and mental illness 177–8
historical overview 167–9
levels of causation 169
  combining levels 172
  contextual level 170–2
  individual level 169–70
  over (life)time 172–4
censoring
  definition 193
Center for Epidemiological Studies Depression Scale (CES-D) 104–6, 203
chance 4
children see depression and anxiety in children and adolescents
Cholera in England 1848–1849 168
  clinical antipsychotic trials of intervention effectiveness (CATIE) 257
  Clinical Interview Schedule (CIS) 209–10
  clozapine 155
  cluster C types 417–18
  clustered categorical data 27
  cocaine 601–2
  Cochran–Mantel–Haentzel test 16–17
  cognitive impairment, mild 541–3
    incidence 543–4
  cognitive impairment no dementia (CIND) 543
  Cohen’s kappa 82
  coherence criterion 110
  cohort studies 5, 56, 62
  Collaborative Longitudinal Personality Disorders Study (CLPS) 406
comorbidity
  axes 9
  definition 191–2
  National Comorbidity Survey (NCS) findings 224
  complementary log–log function 19
  Composite International Diagnostic Interview (CIDI) 204, 208, 209, 222
  concurrent validity 103
  conditional logistic regression 25–6
  conditional tables 16
  confidence intervals 21
  confounding 4
    dealing with 244
      gene–environment interplay 65–6
      population stratification 66
      conscript registers 122
  consistency of association 110
  Consolidated Standards of Reporting Trials (CONSORT) checklist 248, 250–1
construct validity 106
  psychiatric diagnosis 106–7
content validity 100
  assessment 100–2
contingency tables
  $2 \times 2$ analysis 11–13
    odds ratio (OR) 13–15
  $2 \times 2$ table sets analysis 16–17
  matched pair study design 17–18
  $R \times C$ analysis 15–16
  continuation odds 27
  copy number variants (CNVs) 59, 65
  Cornell Selectee Index (CSI) 203
cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1) 257–8
criterion validity 102–6
cross-fostering study design 36
crossing interactions 65
cross-product ratio 13
cross-sectional assessments 103
cumulative logit 27
dementia
  incidence 543–4
  outcomes 548–9
  prevalence 541
  risk factors 545–6
dependent personality disorder 416
depression and anxiety in children and adolescents 435, 443
correlates and risk factors 438, 440
  age and sex 438–9
  combinations of risk factors 442
  early developmental factors 440
  parental and familial factors 441–2
  physical conditions and illness 440–1
  social class, race and ethnicity 439–40
  stressful life events 441
  magnitude
    anxiety disorders 436–7
    mood disorders 435–6
    service patterns and impacts 442–3
depression with atypical features 294
depression with psychotic features 294
depressive disorders 289–90, 304
  as outcome of other conditions 191
dysthymia
  age 303
  comorbidity 304
  definition 302
  gender 303
  marital status 304
  race/ethnicity 303
  rates 302
  risk factors 302–4
  urban–rural residence 304
diabetes 
  incidence 540–1
  outcomes 547–8
  risk factors 544–5
  major depression 301–2
adolescence 297
  age 296–7
  definition 290
  disablement 295
  family history/genetics 300–1
  gender 295–6
  geriatric 297
  incidence 293–4
  marital status 299–300
  measurement 304
  prevalence 291–3
  psychiatric comorbidity 300
  race and ethnicity 297–8
  risk factors 295–301
  secular trends 301
  socioeconomic status 298–9
  subtypes 294–5
  type of rates 290–1
  urban–rural residence 299
risk
  relative and attributable 187
  symptoms
    onset 186–7
    prodrome 187
  women of reproductive age 486–7
descriptive epidemiology 56
developmental abnormalities
  schizophrenia 278
  Diagnostic Interview for Genetic Studies (DIGS) 34
  Diagnostic Interview Schedule (DIS) 76, 100, 203–4, 208, 221
diet
  ADHD 457
diethylstilbestrol (DES) 173
differential effects 111
disability adjust life years (DALYs) 365
disasters see mass disasters and anxiety disorders
discriminant validity 103, 107
dopamine D4 receptor (DRD4)
  ADHD 454
dopamine D5 receptor (DRD5)
  ADHD 454–5
dopamine transporter gene (DAT1, SLC6A3)
  AHDH 455–6
dose–response relationship 6
double-bind trials 246
Down’s syndrome 174
drug use disorders 381, 394
comorbidities with psychiatric and medical conditions 388–91
consumption of drugs 381–4
definitions 384
future opportunities 391–3
genetic epidemiology 391
global rates 387–8
rates of abuse and dependence 384–7
dynamic modelling 178
dysthymia see depressive disorders
eating disorder not otherwise specified (EDNOS) see eating disorders
eating disorders 343
case definition 343–5
comorbidity 351–2
future incidence directions 355–6
incidence studies 351
major prevalence studies 345–8
Australia and New Zealand 350
Europe 350
North America 000
summary 351
mortality 352
risk factors 241
age 352–3
genetic factors 354–5
race/ethnicity 354
sex 352
sociocultural factors 354
sociodemographic factors 352–4
socioeconomic status 352–3
urbanisation 352
effectiveness trials see practical trials
efficacy of trials 251–3
endophenotypes 108–9
enthusiasm hypothesis 140
environmental risk factors 31
environmental exposure
measurement of 59
Epidemiologic Catchment Area (ECA) 203, 221–2
epidemiology
definition 1–2
epigenetic mechanisms 67
epistasis 33
equal-environments assumption 35–6
estimated expected count 14
ethnicity
attention deficit hyperactivity disorder (ADHD) 453
definition 580–1
depression and anxiety in children and adolescents 439–40
dysthymia 303
eating disorders 354
major depression 297–8
panic disorder 315
schizophrenia 269–71
Europe
instruments for epidemiological research 208–10
instruments for psychiatric services and primary care 206–8
European first-episode schizophrenia trials (EUFEST) 258–9
European migrants 579
adverse social experiences 586
area level social processes 586–7
criticisms of social hypotheses and research 589
individual level social processes 587–9
biological considerations
Genetic influences 585
neurodevelopmental insults 585–6
cannabis use 586
defining constructs 579
ethnicity 580–1
migration 579–80
high psychosis rates 581
methodological limitations 581–2
misdiagnosis 582–3
modern studies 583–4
high psychosis rates, possible explanations
selective migration 584–5
implications 590
policy 591
research 590–1
mechanisms 589–90
European Psychiatric Care Assessment Team (EPCAT) 143
European Service Mapping Schedule (ESMS) 143–5
evocative gene–environment correlation (GEr) 57
exact logistic regression 26–7
experimental epidemiology 243
classification of RCTs 251–4
clinical antipsychotic trials of intervention effectiveness (CATIE) 257
INDEX

experimental epidemiology (continued)
cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1) 257–8
effectiveness trials in schizophrenia 255
European first-episode schizophrenia trials (EUFEST) 258–9
non-randomised evidence 243–5
olanzapine 255–6
methodology 257
prioritising control 248–51
random error (noise) 248, 249
result reporting 248
size and cost of trials 259
systematic error (bias) 245
accounting for participants 247
blinding (masking) of treatment allocation 246
empirical evidence of bias 247–8
maximising follow-up 247
randomisation with allocation concealment 245–6
translation of experimental design to real world 245
extended phenotype 55
external validity 112
familial aggregation 56
familial disorders 32
assessment among relatives 33–4
caveats about study interpretation 34–5
family study vs. family history methods 34
proband selection 32–3
family studies 56, 64
family-based association tests (FBATs) 44
Farr, William 168
fetal exposure to alcohol
ADHD 457
fetal exposure to maternal smoking
ADHD 458
first incidence 187–8
Fisher's exact test 14
Five Factor Model (FFM) of personality 421
fluoxetine 155
functioning
definition 192

gender
see also sex differences
dysthymia 303

major depression 295–6
panic disorder 314
schizophrenia 268–9
gene location techniques 39
affected relative pair method 39–40
linkage analysis 39
lod score method 40–1
statistical methods 39
gene–environment interplay 53–4
epigenetic mechanisms 67
forms 55
gene–environment correlation (GER) 55–8
gene–environment interaction (G x E) 58
measurement scale 61–2
models 60–1
study designs 62–5
validity 63–7
measurements
environmental exposure 59

genetic variants 58–9
pathological phenotypes 60
gene–environment wide interaction studies (GEWISs) 59, 64–5
general fertility rate (GFR) 488
General Health Questionnaire (GHQ) 206–7
Generalisability Theory 76
generalisations 112
generalised anxiety disorder (GAD)
definition 318
rates 318–19
risk factors 319
genetic and environmental bases of psychiatric disorders 87–9
combined influences 92–3
mediation 93
moderation 92–3
proxies 93–4
risk factors, independent 93
risk factors, overlapping 94
extensions
multiple risk factors at multiple time points 95
multiple risk factors at two time points 95
one risk factor at two time points 94–5
further considerations 95–6
methodological barriers
case–control studies 89
correlation vs. interaction 92
odds ratio 90–2
statistical significance 89–90
genetic epidemiology 1, 31, 53–4
process 54–5
psychiatric genetics and psychiatric epidemiology 44–5
research 31–2
familial disorders 32–5
gene location 39–41
gene/environment relative contributions 35–7
risk-conferring variants 41–4
transmission mode 37–9
genetic exposure 56
genetic variants
measurement of 58–9
genome-wide association studies (GWASs) 55
genomic control approaches 66
geriatric depression 297
geriatric psychiatry 534
aetiological studies 544
case distribution 536–9
depressive disorder 539–40
incidence of dementia 543–4
incidence of depression 540–1
mild cognitive impairment 541–3
prevalence of dementia 541
subsyndromal depression 540
case identification 535–6
comorbidity of depression and dementia 546
health care service use 550
historical trends in epidemiology 549–50
suicide 550
outcomes 547
dementia 548–9
depressive disorders 547–8
risk factors
dementia 545–6
depression 544–5
goodness-of-fit 25

haplotypes 59
Health Opinion Survey (HOS) 203
health services research (HSR) 133–4
heroin 603
history effects 111
histrionic personality disorder 411
Hopkins Symptom Checklist (HSCL) 205
hyperkinetic disorder (HKD) 449
differentiation from ADHD 450
hypothesis testing 21

identical by descent (IBD) 64
immune function
schizophrenia 279
incidence
definition 187
infections
schizophrenia 278–9
inference for a single proportion 10–11
influenza infection
schizophrenia 563
intensive case management (ICM) 149
interaction between predictor variables 24–5
interclass correlation 78–9
internal consistency 75
internal validity 110
inverse normal function 19
IQ
birthweight 176–7
item response theory 83

Japan, epidemiological studies 559–60, 572
affective disorders 566
pre- and postnatal depression 568–9
prevalence of depressive disorder 567–8
autism spectrum disorders 569
factors accounting for increasing prevalence 571–2
prevalence 569–71
routine health checkup system 569

schizophrenia
factors affecting course and treatment 565–6
influenza infection 563
methamphetamine (MAP) psychosis 563–4
obstetric complications 562–3
prevalence and incidence 560–1
radiation 565
seasonality of birth 561–2

Jeffrey’s interval 11

Koch, Robert 168

Latin American populations in USA 595, 611
alcohol and drug use 600
alcohol abuse 600–1
Latin American populations in USA (continued)
cocaine 601–2
drug use 601
heroin 603
marihuana 602–3
methamphetamines (MAPs) 603–4
countries of origin 597–9
definition of migration 595–7
dependence and treatment rates 604
drugs and HIV/AIDS 601
emigration process 606–8
migrant living conditions 599–600
returning migrants 611
substance abuse and service access 608–10
liability 38–9, 54
lifetime comorbidity 191
likelihood ratio test (LRT) 14, 15–16, 21
linkage analysis 39, 54
linkage disequilibrium (LD) mapping 42, 54–5
lod score method 40–1
logistic function 19
logistic regression 18–20
conditional 25–6
confidence intervals 21
exact 26–7
goodness-of-fit 25
hypothesis testing 21
interactions 24–5
interpretation of coefficients 20–2
multiple logistic regression 22–3
polytomous 27–8
predictors with more than 2 levels 23–4
logit function 19
major depressive disorder (MDD) 289
see also depressive disorders
validity of construct 99–100
major depressive episodes (MDEs) 289
marihuana 602–3
marital status
dysthymia 304
major depression 299–300
schizophrenia 269
masking of treatment allocation 246
mass disasters and anxiety disorders 320–1
Hurricane Katrina 321
limitation of epidemiologic studies 322
September 11 terrorist attacks 321
tsunami in southern Thailand 321–2
matched pair study design 17–18
matching fallacy 33
McNemar’s test for matched pairs 17–18
measles, mumps and rubella (MMR) vaccine 472, 477
Japan 571–2
mediators 87–9
Medical Outcomes Study (MOS) 206
Mental Health Atlas (WHO) 142–3
mental health services research 133–4, 152
definition 134–5
framework 135–6
key concepts 137
appropriateness of care 138–9
efficacy, effectiveness and efficiency 137–8
equity 140–1
factors associated with access to health care 140
need 137
small area variations (SAV) 139–40
want, demand and supply 137
studies 141
administrative data 141–7
primary data collection 147–50
qualitative 150–2
Mental Status Schedule (MSS) 206
methamphetamine (MAP) psychosis
schizophrenia 563–4
methamphetamines (MAPs)
abuse in Latin American populations in USA 603–4
micro shared environments 59
minor physical abnormalities (MPAs)
schizophrenia 277–8
moderators 87–9
modernisation
schizophrenia 271
monozygotic (MZ) twins 33
gene/environment studies 35–6
mortality 192
mortality effects 112
multidimensional contingency table 16
multifactorial polygenic (MFP) model 38, 54
multigenerational pedigree studies 64
multinomial regression models 27–8
multiple logistic regression 22–3
narcissistic personality disorder 416
National Comorbidity Survey (NCS) 221, 236
adolescent supplement (NCS-A)
design and rationale 233–4
findings 234
baseline
age at onset 224
background and design 221–2
comorbidity 224
findings 222–7
lifetime and prevalence of DSM disorders 223–4
primary and secondary disorders 225
primary prevention of secondary disorders 227
pure and comorbid lifetime disorders 225
societal costs of mental disorders 225–6
treatment 226–7
follow-up survey (NCS-2)
design and rationale 227–8
findings 228–9
prevalence trends 231
progression of disorders 228–9
risk factors 228
replication (NCS-R) 204, 221
design and rationale 229–31
prevalence bias 193–4
recognition 194–5
statistical techniques 195
natural history of psychopathology 183, 195
course
remission 188–91
methodology 192
attrition 192–3
censoring 193
prevalence bias 193–4
recall 194–5
statistical techniques 195
onset 183–6
population measures 187–8
prodromes and precursors 186–7
outcome 191
comorbidity 191–2
functioning 192
mortality 192
Neuropsychiatric Screening Adjunct (NSA) 203
noise (random error) 248, 249
nominal variables 9
nomologic network 106
non-affective remitting psychosis (NARP) 486
non-causal gene–environment correlation (GER) 57
non-randomised evidence, limitations of 243–5
Nordic Countries’ psychiatric epidemiology registers 117
cause of death 121
Denmark 122–3
epidemiological benefits 127
findings 126
Finland 123–4
hospital discharge 120
medication data 120–1
methodological and administrative challenges 126–7
Norway 124–5
other registers 121–2
psychiatric research 118–20
Sweden 125–6
North America
instruments for epidemiological research 202–5
instruments for psychiatric services and primary
care 205–6
null value 13
number needed to take (NNT) 90
obsessive–compulsive disorder (OCD)
definition 319–20
rates 320
risk factors 320
obsessive–compulsive personality disorder 416–19
obstetric complications (OCs) 487, 490, 492
Japan
schizophrenia 562–3
risk of adult onset mental disorder in offspring 493–4
influence of maternal smoking 496
measurement 494–5
mechanisms of risk 495–6
origin of risks 494
specificity of risk 495
odds ratio (OR) 13–15, 20–2
not clinically interpretable 90–2
olanzapine
cost-effectiveness trial 255–6
methodology 257
oligogenic models 54
omega coefficient 75
oppositional defiant disorder (ODD) 333
ordinal variables 9
outcome
definition 191
overmatching 33
panic disorder
comorbid psychiatric disorder 315–16
definition 313
rates 313–14
risk factors
age 314
gender 314
race/ethnicity 315
parallelism 61
paranoid personality disorder 407
parental age
schizophrenia 276
parent-as-proband study design 36
partial tables 16
passive gene–environment correlation (GEr) 57
pathological phenotypes
measurement of 60
Patient Health Questionnaire (PHQ-S) 206
patient practice variations hypothesis 140
Pearson chi-square test 14, 15–16
penetrance 38
performance bias 246
Personal Health Questionnaire (PHQ-G) 207
personality disorder not otherwise specified
(PDNOS) 420
personality disorders (PDs) 401–2
conceptual issues 419
course, prognosis and developmental issues 404–6
future directions 427–8
methodological issues
collecting diagnostic information 423–4
comorbidity and diagnostic overlap 424–7
diagnostic 422–3
diagnostic agreement 424
physical health 426–7
models 419–20
distinguishing Axis I from Axis II 421–2
issues and challenges for DSM-V 420–1
specific prevalence 407
antisocial personality disorder (APD) 410–11
avoidant personality disorder 416
borderline personality disorder (BPD) 411
cluster A types 408–10
cluster B types 412–5
cluster C types 417–18
dependent personality disorder 416
histrionic personality disorder 411
narcissistic personality disorder 416
obsessive–compulsive personality disorder 416–19
paranoid personality disorder 407
schizoid personality disorder 407
schizotypal personality disorder 410
substantive findings 402
treated prevalence 406–7
personality traits 401
pervasive developmental disorder, not otherwise specified (PDD-NOS) 469
pharmacoepidemiology 155–6, 162–3
data sources 157–8
governmental administrative 158
health maintenance organizations 158
large-scale surveys 158–9
practice-based networks 159
overview
historical perspective 156–7
recent studies 159
adverse effects and unanticipated benefits 159–60
descriptive analyses 161
optimising use 161–2
pharmacoeconomic analyses 161
phenylketonuria (PKU) 420
polytomous logistic regression 27–8
population stratification confounding 66
population-attributable fraction (PAF) 122
Positive and Negative Syndrome Scale (PANSS) 566
positive predictive value 105
post-dictive validity 103
postnatal depression 502–3
post-traumatic stress disorder (PTSD) 320–1
Hurricane Katrina 321
September 11 terrorist attacks 321
tsunami in southern Thailand 321–2
poverty see socioeconomic status
practical (pragmatic; effectiveness) trials 253
schizophrenia 255
predictive validity 103
pregnancy and delivery problems
ADHD 457
pregnancy
mental illness in mother
fetal exposure to behavioural or modifiable risk factors 488–90
neuropathic outcomes for children 491–2
parenting outcomes 492–3
physical outcomes for children 491
pregnancy outcomes 490–1
schizophrenia 276–7
prescription databases 121
Present State Examination (PSE) 207–8
prevalence bias 193–4
prevalence of DSM disorders
National Comorbidity Survey (NCS) 223–4
Primary Care Evaluation of Mental Disorder (PRIME-MD) 206
proband selection 32–3
probit function 19
prodrome
definition 186
product moment correlation 82–3
Psychiatric Epidemiologic Research Instrument (PERI) 203
psychiatric epidemiology 44–5
definition 2
future directions 7, 167, 178–9
psychiatric genetics 44–5
Psychiatric Status Schedule (PSS) 206
psychiatric syndrome 210
quality adjusted life year (QALY) 161
quasi-experimental studies 110
race
depression and anxiety in children and adolescents 439–40
dysthymia 303
eating disorders 354
major depression 297–8
panic disorder 315
radiation
schizophrenia 565
random error (noise) 248, 249
randomised controlled trials (RCTs) 1, 3, 243, 244
advantages and disadvantages 245
classification 251–4
clinical antipsychotic trials of intervention
effectiveness (CATIE) 257
composition 4
cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1) 257–8
effectiveness trials in schizophrenia 255
European first-episode schizophrenia trials (EUFEST) 258–9
olanzapine 255–6
methodology 257
prioritising control 248–51
random error (noise) 248, 249
result reporting 248
size and cost of trials 259
systematic error (bias) 245
accounting for participants 247
blinding (masking) of treatment allocation 246
empirical evidence of bias 247–8
maximising follow-up 247
randomisation with allocation concealment 245–6
translation of experimental design to real world 245
reactive gene–environment correlation (GER) 57
recall bias 5–6
definition 194–5
receiver operating characteristic (ROC) analysis 104, 105
recurrence
definition 189
regression to the mean 111
relapse
definition 189
relative risk (RR) 13
reliability 73, 83
binary judgements 77–8
estimation 74–6
effect of population variance 76
statistical methods 78–9
Cohen’s kappa 82
Cronbach’s alpha 82
item response theory 83
one-way ANOVA 79–80
product moment correlation 82–3
two-way ANOVA 80–1
statistical remedies for low reliability 76–7
reliability coefficient 73–4
remission 188–91
response bias 75
retrospective assessments 103
reverse causation 6
risk factors 2
  individual level 169–70
risk-conferring variants of genes 41–4
risperidone 155
Rutter’s index of ADHD 458
sample size 66–7
sampling variation 4
Sanitarians 168
scales and schedules for psychopathology 199–202, 210–12
  European instruments for epidemiological research 208–10
  European instruments for psychiatric services and primary care 206–8
  North American instruments for epidemiological research 202–5
  North American instruments for psychiatric services and primary care 205–6
SCAN scale 189
Schedule for Affective Disorders and Schizophrenia (SADS) 100, 203, 206
schedules for psychopathology see scales and schedules for psychopathology
schizoid personality disorder 407
schizophrenia 263, 280
biological risk factors
  childhood developmental abnormalities 278
genes 272–5
  immune function 279
infections 278–9
  minor physical abnormalities (MPAs) 277–8
parental age 276
pregnancy and birth complications 276–7
winter birth 275–6
course and outcome in developing and developed countries 176
demographic correlates
  age and sex 268–9
  marital status 269
  socioeconomic position 269
early detection and intervention 617–18
clinical implications 627
future directions 626–7
gene-based vs. genome-based research 624–6
modelling genetic and phenotypic heterogeneity 618–20
  syndrome definition 620–2
effectiveness trials 255
incidence 265, 266
methods
  case identification 263–4
  case-finding 264
natural history
  course 266–7
  mortality 268
  onset 265–6
  outcome 267–8
  prevalence 264–5
  prevention 279–80
social risk factors
  ethnicity 269–71
  modernisation 271
  substance use 271–2
  urban residence 271
women of reproductive age 484–6
schizotypal personality disorder 410
score test 14
segregation analyses 56
selection bias 5, 246
selection effects 112
selective gene–environment correlation (GEr) 57
serotonin 1B receptor
  ADHD 456
serotonin transporter (HTT, SLC6A4)
  ADHD 456
sex differences
  see also women, mothers and their children
  attention deficit hyperactivity disorder (ADHD) 452
depression and anxiety in children and adolescents 438–9
eating disorders 352
sharing pattern of alleles 64
sib-pair analyses 64
significance, statistical 89–90
simple sequence repeats (SSRs) 59
single nucleotide polymorphisms (SNPs) 59, 64–5
smoking
  fetal exposure to maternal smoking
  ADHD 458
risk of obstetric complications 496
Snow, John 168
social phobia
  definition 317
  rates 317–18
  risk factors 318
social welfare registers 122
socioeconomic status (SES) 25
  attention deficit hyperactivity disorder (ADHD) 453
  depression and anxiety in children and adolescents 439–40
  eating disorders 352–3
  major depression 298–9
  schizophrenia 269
Spearman–Brown formula 76–7
specificity 110
speed of remission 189
statistical methods 9–10, 29
  advanced topics 25
    clustered categorical data 27
    conditional logistic regression 25–6
    exact logistic regression 26–7
    multinomial regression models 27–8
  analysis of $2 \times 2$ contingency table sets 16–17
    matched pair study design 17–18
  analysis of $2 \times 2$ contingency tables 11–13
    odds ratio (OR) 13–15
  analysis of $R \times C$ contingency tables 15–16
  inference for a single proportion 10–11
  logistic regression 18–20
    confidence intervals 21
    goodness-of-fit 25
    hypothesis testing 21
    interactions 24–5
    interpretation of coefficients 20–2
    multiple logistic regression 22–3
    predictors with more than 2 levels 23–4
statistical regression artefacts 111
statistical significance 89–90
stress
  maternal antenatal 498–9
Structured Clinical Interview for DSM-III-R (SCID) 222
substance use
  schizophrenia 271–2
subsyndromal depression 540
sufficient causal pies 58
sufficient-component cause framework 58
suicide and attempted suicide 517, 526
  definitions 517–18
  older adults 530
perinatal maternal mental illness 503–4
  prevalence 518–19
  attempted suicide, suicide ideation and planning 519
  global prevalence 519
  United States – attempted suicide, suicide ideation and planning 520
  United States – suicide attempted, suicide ideation and planning 519–21
protective factors 526
risk factors
  aggression and impulsivity 525
  alcohol and substance use disorders 522
  anxiety disorders 522
  biological risk factors 524
  childhood abuse 525
  clinical and psychosocial factors 525
  genetic risk factors 523–4
  hopelessness 525
  life events and psychosocial stressors 525–6
  mental illness 520–1
  mood disorders 521–2
  neuropsychiatric disorders and head injury 523
  personality disorders 522
  psychiatric comorbidity 523
  psychotic disorders 522
  women of reproductive age 487
symptoms of psychopathology
  course
    remission 188–91
  onset 183–6
    age at onset 224
    population measures 187–8
    prodromes and precursors 186–7
scales 199–202
  European instruments for epidemiological research 208–10
  European instruments for psychiatric services and primary care 206–8
  North American instruments for epidemiological research 202–5
  North American instruments for psychiatric services and primary care 205–6
synaptosomal associated protein of 25 kD (SNAP25) 456
ADHD 456
syndrome 210
definition 199
television watching
ADHD 459–60
testing and instrumentation effects 111
test–retest design 74–5
time sequence 110
total incidence 187–8
toxin exposure
ADHD 457
transitions in drug use 383
translational medicine 7
transmission disequilibrium test (TDT) 43–4
transmission mode of genetic disorders 37
mathematical modelling 37–8
model types 38–9
Tridimensional Personality Questionnaire (TPQ) 102
Twenty-Two Item Scale (22IS) 203
uncertainty hypothesis 139–40
urban living
dysthymia 304
eating disorders 352
major depression 299
schizophrenia 271
validity 73, 99, 112–13
between variables 110–12
constructs 99–100
construct validity 106
construct validity, application to psychiatric diagnosis 106–7
content validity 100
content validity, assessment of 100–2
Criterion validity 102–6
psychiatric disorders 107–10
valproate 155
Wald test 14, 21
wealth see socioeconomic status
Wilson confidence interval 10–11
winter birth
schizophrenia 275–6
women, mothers and their children 483, 507
epidemiology of mental illness 484
depression 486–7
schizophrenia 484–6
suicide 487
fertility and fecundity in mental illness 487–8
gene–environment interactions and offspring outcomes 493
mental illness at conception and during pregnancy
fetal exposure to behavioural or modifiable risk factors 488–90
neuropathic outcomes for children 491–2
parenting outcomes 492–3
physical outcomes for children 491
pregnancy outcomes 490–1
obstetric complication risks 493–4
influence of maternal smoking 496
measurement 494–5
mechanisms of risk 495–6
origin of risks 494
specificity of risk 495
parental condition 496
age 496–7
antenatal maternal stress 498–9
nutrition 497–8
perinatal maternal mental illness 500
definition 500
postnatal depression 502–3
postpartum psychosis 500–1
specificity and duration of risk 501–2
suicide 503–4
study design 504–7
World Health Organization (WHO)
Alcohol, Drug Abuse, and Mental Health Administration (WHO-ADAMAHA) 208
Mental Health Atlas 142–3
World Mental Health (WMH) Survey Initiative 147–8, 208–9
design and rationale 234–5
findings
cross-national correlates 236
diagnostic criteria 234–5
disorder prevalence 234
relative impairments 234
treatment 234
Z statistic 23